• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Pain - Pipeline Review, H2 2012 Product Image

Pain - Pipeline Review, H2 2012

  • ID: 2335115
  • November 2012
  • 294 pages
  • Global Markets Direct

Pain – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pain - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pain. Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pain.
- A review of the Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 7
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Pain Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Pain 13
Pain Therapeutics under Development by Companies 15
Pain Therapeutics under Investigation by Universities/Institutes 27
Late Stage Products 32
Comparative Analysis 32
Mid Clinical Stage Products 33
Comparative Analysis 33
Early Clinical Stage Products 34
Comparative Analysis 34
Discovery and Pre-Clinical Stage Products 35
Comparative Analysis 35
Pain Therapeutics – Products under Development by Companies 36
Pain Therapeutics – Products under Investigation by Universities/Institutes 52
Companies Involved in Pain Therapeutics Development 57
Bristol-Myers Squibb Company 57
DURECT Corporation 58
Boehringer Ingelheim GmbH 59
Kyowa Hakko Kirin Co., Ltd. 60
Abbott Laboratories 61
Allergan, Inc. 62
AlphaRx, Inc. 63
Amgen Inc. 64
Sanofi-Aventis 65
AstraZeneca PLC 66
BioDelivery Sciences International, Inc. 67
GlaxoSmithKline plc 68
Alkermes, Inc. 69
Infinity Pharmaceuticals, Inc. 70
Generex Biotechnology Corporation 71
Egalet a/s 72
Meytav Technological Incubator 73
Alexza Pharmaceuticals, Inc. 74
Zogenix, Inc. 75
Neurocrine Biosciences, Inc. 76
AcelRx Pharmaceuticals, Inc. 77
Astellas Pharma Inc. 78
Daewoong Pharmaceutical Co., Ltd. 79
Eisai Co., Ltd. 80
Esteve Group 81
Orion Corporation 82
Pfizer Inc. 83
Purdue Pharma L.P. 84
Vernalis plc 85
Collegium Pharmaceutical, Inc. 86
Merck KGaA 87
Acura Pharmaceuticals, Inc. 88
Alchemia Limited 89
Addex Pharmaceuticals 90
EpiCept Corporation 91
Evotec Aktiengesellschaft 92
GW Pharmaceuticals plc 93
Icagen Inc 94
AVANIR Pharmaceuticals 95
LifeCycle Pharma A/S 96
Lpath, Inc. 97
NeurogesX, Inc. 98
NeuroSearch A/S 99
NexMed, Inc. 100
Novogen Limited 101
Columbia Laboratories Inc. 102
Nutra Pharma Corporation 103
Paladin Labs Inc. 104
Arena Pharmaceuticals, Inc. 105
Elite Pharmaceuticals, Inc. 106
Flamel Technologies S.A. 107
Array BioPharma Inc. 108
Phytopharm Plc 109
Ahn-Gook Pharmaceutical Co., Ltd. 110
PhytoHealth Corporation 111
Diamyd Medical AB 112
Neurim Pharmaceuticals (1991) Ltd. 113
Suven Life Sciences Ltd. 114
Proximagen Neuroscience plc. 115
Newron Pharmaceuticals S.p.A. 116
Teikoku Pharma USA, Inc. 117
Xel Pharmaceuticals, Inc. 118
Dharma Therapeutics, Inc. 119
Angelini Group 120
Axxam SpA 121
Lehigh Valley Technologies, Inc. 122
Camurus AB 123
AnaMar Medical AB 124
Probiodrug AG 125
Phosphagenics Limited 126
Abiogen Pharma S.p.A. 127
Physica Pharma 128
Neorphys 129
MIKA Pharma GmbH 130
Xenon Pharmaceuticals Inc. 131
CREABILIS Therapeutics S.r.l. 132
Oncodesign SA 133
Ascent Therapeutics 134
Alder Biopharmaceuticals Inc. 135
AngioChem Inc. 136
PharmEste 137
Trevena, Inc. 138
Arcion Therapeutics, Inc. 139
PLx Pharma Inc. 140
Solace Pharmaceuticals 141
Hydra Biosciences, Inc. 142
NeurAxon, Inc. 143
SeneXta Therapeutics SA 144
Logical Therapeutics, Inc. 145
QRxPharma Limited 146
Sosei Co. Ltd. 147
BioStar Pharmaceuticals, Inc. 148
Cara Therapeutics, Inc. 149
Amneal Pharmaceuticals, L.L.C. 150
Kalypsys, Inc. 151
PepTcell Limited 152
Tragara Pharmaceuticals, Inc. 153
Intellipharmaceutics International Inc. 154
KYORIN Pharmaceutical Co., Ltd. 155
Lipopharma 156
Winston Pharmaceuticals, Inc. 157
Encore Therapeutics Inc. 158
SantoSolve AS 159
Bial - Portela & Ca, S.A. 160
KemPharm, Inc. 161
Spinifex Pharmaceuticals Pty Limited 162
Heptares Therapeutics Ltd. 163
Envoy Therapeutics, Inc. 164
Flexion Therapeutics 165
BioProspecting NB, Inc. 166
Troikaa Pharmaceuticals Ltd. 167
SelectX Pharmaceuticals, Inc. 168
TheraQuest Biosciences, LLC 169
iCeutica, Inc. 170
Celtic Pharmaceutical Holdings L.P. 171
Reviva Pharmaceuticals Inc. 172
Mt Cook Pharma. Inc. 173
Naurex, Inc. 174
Colorectal Cancer – Therapeutics Assessment 175
Assessment by Monotherapy Products 175
Assessment by Combination Products 176
Assessment by Route of Administration 177
Assessment by Molecule Type 179
Drug Profiles 181
oxycodone ER - Drug Profile 181
ketoprofen - Drug Profile 183
ALO-02 - Drug Profile 184
diclofenac sodium - Drug Profile 186
buprenorphine hydrochloride - Drug Profile 187
Tramadol + Acetaminophen - Drug Profile 189
Prodrug OF Hydrocodone - Drug Profile 191
sufentanil + triazolam - Drug Profile 193
hydrocodone bitartrate ER - Drug Profile 195
aspirin - Drug Profile 197
Ketorolac + Lidocaine - Drug Profile 199
ropivacaine - Drug Profile 201
naproxen - Drug Profile 202
duloxetine hydrochloride - Drug Profile 204
Solumedrol + Prednisone - Drug Profile 205
Zushima - Drug Profile 207
nabilone - Drug Profile 208
lidocaine - Drug Profile 210
oxycodone ER - Drug Profile 211
phenazopyridine hydrochloride - Drug Profile 212
Acetaminophen + Ibuprofen - Drug Profile 213
ibuprofen + paracetamol - Drug Profile 214
Varicella-zoster vaccine - Drug Profile 215
Mitoxantrone + Prednisone + Clodronate - Drug Profile 216
Carboplatin + Glutathione + Paclitaxel - Drug Profile 218
fentanyl citrate - Drug Profile 220
fentanyl citrate - Drug Profile 221
nitrous oxide - Drug Profile 222
remifentanil hydrochloride - Drug Profile 223
Methylprednisolone + Prednisone - Drug Profile 224
Mitoxantrone + Prednisone - Drug Profile 225
Nuedexta - Drug Profile 226
dexamethasone acetate - Drug Profile 228
F-0434 - Drug Profile 229
Gabapentine - Drug Profile 230
eslicarbazepine acetate - Drug Profile 231
E2000 + Diclofenac Sodium - Drug Profile 233
lidocaine Patch - Drug Profile 234
Drug For Inflammation And Autoimmune Diseases - Drug Profile 235
hydrocodone bitartrate - Drug Profile 236
Diclofenac + Thiocolchicoside - Drug Profile 237
Dexmedetomidine - Drug Profile 239
Fentanyl Iontophoretic Transdermal System - Drug Profile 240
Pain Therapeutics – Drug Profile Updates 241
Pain Therapeutics – Discontinued Products 262
Pain Therapeutics - Dormant Products 266
Colorectal Cancer – Product Development Milestones 283
Featured News & Press Releases 283
Appendix 290
Methodology 290
Coverage 290
Secondary Research 290
Primary Research 290
Expert Panel Validation 290
Contact Us 291
Disclaimer 291

List of Tables
Number of Products Under Development for Pain, H2 2012 16
Products under Development for Pain – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Development by Companies, H2 2012 (Contd..4) 23
Number of Products under Development by Companies, H2 2012 (Contd..5) 24
Number of Products under Development by Companies, H2 2012 (Contd..6) 25
Number of Products under Development by Companies, H2 2012 (Contd..7) 26
Number of Products under Development by Companies, H2 2012 (Contd..8) 27
Number of Products under Development by Companies, H2 2012 (Contd..9) 28
Number of Products under Development by Companies, H2 2012 (Contd..10) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 34
Comparative Analysis by Late Stage Development, H2 2012 35
Comparative Analysis by Mid Clinical Stage Development, H2 2012 36
Comparative Analysis by Early Clinical Stage Development, H2 2012 37
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 38
Products under Development by Companies, H2 2012 39
Products under Development by Companies, H2 2012 (Contd..1) 40
Products under Development by Companies, H2 2012 (Contd..2) 41
Products under Development by Companies, H2 2012 (Contd..3) 42
Products under Development by Companies, H2 2012 (Contd..4) 43
Products under Development by Companies, H2 2012 (Contd..5) 44
Products under Development by Companies, H2 2012 (Contd..6) 45
Products under Development by Companies, H2 2012 (Contd..7) 46
Products under Development by Companies, H2 2012 (Contd..8) 47
Products under Development by Companies, H2 2012 (Contd..9) 48
Products under Development by Companies, H2 2012 (Contd..10) 49
Products under Development by Companies, H2 2012 (Contd..11) 50
Products under Development by Companies, H2 2012 (Contd..12) 51
Products under Development by Companies, H2 2012 (Contd..13) 52
Products under Development by Companies, H2 2012 (Contd..14) 53
Products under Development by Companies, H2 2012 (Contd..15) 54
Products under Investigation by Universities/Institutes, H2 2012 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 59
Bristol-Myers Squibb Company, H2 2012 60
DURECT Corporation, H2 2012 61
Boehringer Ingelheim GmbH, H2 2012 62
Kyowa Hakko Kirin Co., Ltd., H2 2012 63
Abbott Laboratories, H2 2012 64
Allergan, Inc., H2 2012 65
AlphaRx, Inc., H2 2012 66
Amgen Inc., H2 2012 67
Sanofi-Aventis, H2 2012 68
AstraZeneca PLC, H2 2012 69
BioDelivery Sciences International, Inc., H2 2012 70
GlaxoSmithKline plc, H2 2012 71
Alkermes, Inc., H2 2012 72
Infinity Pharmaceuticals, Inc., H2 2012 73
Generex Biotechnology Corporation, H2 2012 74
Egalet a/s, H2 2012 75
Meytav Technological Incubator, H2 2012 76
Alexza Pharmaceuticals, Inc., H2 2012 77
Zogenix, Inc., H2 2012 78
Neurocrine Biosciences, Inc., H2 2012 79
AcelRx Pharmaceuticals, Inc., H2 2012 80
Astellas Pharma Inc., H2 2012 81
Daewoong Pharmaceutical Co., Ltd., H2 2012 82
Eisai Co., Ltd., H2 2012 83
Esteve Group, H2 2012 84
Orion Corporation, H2 2012 85
Pfizer Inc., H2 2012 86
Purdue Pharma L.P., H2 2012 87
Vernalis plc, H2 2012 88
Collegium Pharmaceutical, Inc., H2 2012 89
Merck KGaA, H2 2012 90
Acura Pharmaceuticals, Inc., H2 2012 91
Alchemia Limited, H2 2012 92
Addex Pharmaceuticals, H2 2012 93
EpiCept Corporation, H2 2012 94
Evotec Aktiengesellschaft, H2 2012 95
GW Pharmaceuticals plc, H2 2012 96
Icagen Inc, H2 2012 97
AVANIR Pharmaceuticals, H2 2012 98
LifeCycle Pharma A/S, H2 2012 99
Lpath, Inc., H2 2012 100
NeurogesX, Inc., H2 2012 101
NeuroSearch A/S, H2 2012 102
NexMed, Inc., H2 2012 103
Novogen Limited, H2 2012 104
Columbia Laboratories Inc., H2 2012 105
Nutra Pharma Corporation, H2 2012 106
Paladin Labs Inc., H2 2012 107
Arena Pharmaceuticals, Inc., H2 2012 108
Elite Pharmaceuticals, Inc., H2 2012 109
Flamel Technologies S.A., H2 2012 110
Array BioPharma Inc., H2 2012 111
Phytopharm Plc, H2 2012 112
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 113
PhytoHealth Corporation, H2 2012 114
Diamyd Medical AB, H2 2012 115
Neurim Pharmaceuticals (1991) Ltd., H2 2012 116
Suven Life Sciences Ltd., H2 2012 117
Proximagen Neuroscience plc., H2 2012 118
Newron Pharmaceuticals S.p.A., H2 2012 119
Teikoku Pharma USA, Inc., H2 2012 120
Xel Pharmaceuticals, Inc., H2 2012 121
Dharma Therapeutics, Inc., H2 2012 122
Angelini Group, H2 2012 123
Axxam SpA, H2 2012 124
Lehigh Valley Technologies, Inc., H2 2012 125
Lipopharma, H2 2012 159
Assessment by Monotherapy Products, H2 2012 178
Assessment by Combination Products, H2 2012 179
Assessment by Stage and Route of Administration, H2 2012 181
Assessment by Stage and Molecule Type, H2 2012 183
Pain Therapeutics – Drug Profile Updates 244
Pain Therapeutics – Discontinued Products 265
Pain Therapeutics – Discontinued Products (Contd..1) 266
Pain Therapeutics – Discontinued Products (Contd..2) 267
Pain Therapeutics – Discontinued Products (Contd..3) 268
Pain Therapeutics – Dormant Products 269
Pain Therapeutics – Dormant Products (Contd..1) 270
Pain Therapeutics – Dormant Products (Contd..2) 271
Pain Therapeutics – Dormant Products (Contd..3) 272
Pain Therapeutics – Dormant Products (Contd..4) 273
Pain Therapeutics – Dormant Products (Contd..5) 274
Pain Therapeutics – Dormant Products (Contd..6) 275
Pain Therapeutics – Dormant Products (Contd..7) 276
Pain Therapeutics – Dormant Products (Contd..8) 277
Pain Therapeutics – Dormant Products (Contd..9) 278
Pain Therapeutics – Dormant Products (Contd..10) 279
Pain Therapeutics – Dormant Products (Contd..11) 280
Pain Therapeutics – Dormant Products (Contd..12) 281
Pain Therapeutics – Dormant Products (Contd..13) 282
Pain Therapeutics – Dormant Products (Contd..14) 283
Pain Therapeutics – Dormant Products (Contd..15) 284
Pain Therapeutics – Dormant Products (Contd..16) 285

List of Figures
Number of Products under Development for Pain, H2 2012 16
Products under Development for Pain – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 30
Late Stage Products, H2 2012 35
Mid Clinical Stage Products, H2 2012 36
Early Clinical Stage Products, H2 2012 37
Discovery and Pre-Clinical Stage Products, H2 2012 38
Assessment by Monotherapy Products, H2 2012 178
Assessment by Combination Products, H2 2012 179
Assessment by Route of Administration, H2 2012 180
Assessment by Stage and Route of Administration, H2 2012 181
Assessment by Molecule Type, H2 2012 182
Assessment by Stage and Molecule Type, H2 2012 183

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos